EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease

Tadashi Ichimiya, Tomoe Kazama, Keisuke Ishigami iD, Yoshihiro Yokoyama, Yuki Hayashi, Satoshi Takahashi, Takao Itoi, Hiroshi Nakase iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0286415 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Tadashi Ichimiya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD) is a chronic intestinal disorder characterized by recurrent flare-ups and remission. Leucine-rich α2-glycoprotein (LRG) has been developed as a new serum biomarker of disease activity in patients with IBD. However, there have been no reports on whether plasma LRG can be used as an alternative to serum LRG. Therefore, in this retrospective study, we evaluated the usefulness of plasma LRG compared to serum LRG.

Methods

We conducted a single-center retrospective observational study. A total of 108 IBD patients (ulcerative colitis [UC], 56; Crohn’s disease [CD], 52) who received treatment at Sapporo Medical University Hospital between August 2020 and September 2021 were enrolled. Serum and plasma LRG levels were measured using the NANOPIA LRG kit. Disease activity was assessed using the Crohn’s Disease Activity Index (CDAI) for CD and partial Mayo (pMayo) score for UC. Endoscopic activity was evaluated using the Mayo Endoscopic Subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with UC and the Simple Endoscopic Score for Crohn’s Disease (SES-CD) score in patients with CD.

Results

Serum LRG levels significantly correlated with plasma LRG levels ( r = 0.990, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansLeucineColonoscopyRetrospective StudiesBiomarkersGlycoproteinsSeverity of Illness Index

Substanzen

LeucineBiomarkersGlycoproteins

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
  • Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.

ORCID-Profile: Keisuke Ishigami, Hiroshi Nakase

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Ichimiya, T., Kazama, T., Ishigami, K., Yokoyama, Y., Hayashi, Y., Takahashi, S., Itoi, T., & Nakase, H. (2023). Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0286415

Vancouver

Ichimiya T, Kazama T, Ishigami K, Yokoyama Y, Hayashi Y, Takahashi S, et al. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease. PLOS ONE. 2023. doi:10.1371/journal.pone.0286415

BibTeX
@article{Ichimiya2023,
  author = {Ichimiya, Tadashi and Kazama, Tomoe and Ishigami, Keisuke and Yokoyama, Yoshihiro and Hayashi, Yuki and Takahashi, Satoshi and Itoi, Takao and Nakase, Hiroshi},
  title = {Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0286415}
}
Kostenlos starten →